– USA, CA – CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that Amy Abernethy, MD PhD is joining the CareDx Board of Directors.
Amy serves as chief medical officer, chief scientific officer and senior vice president for oncology at Flatiron Health, a health technology company focused on building a cancer data platform to accelerate research and improve day-to-day cancer care. Flatiron is a hyper-growth company that started in 2012 and was acquired by Roche Group in 2018 for $2.1 billion. She also serves on the Board of Directors for athenahealth (NASDAQ:ATHN).
Before joining Flatiron, Amy was professor of medicine at Duke University School of Medicine and ran the Center for Learning Health Care in the Duke Clinical Research Institute and Duke Cancer Care Research Program in the Duke Cancer Institute. She maintains an adjunct professorship with Duke.
“Amy brings tremendous expertise generating insights from large patient data sets and building learning healthcare systems. As we further define CareDx’s approach to genomic information and patient care management, her contributions will be invaluable,” said Michael Goldberg, CareDx Chairman of the Board of Directors.
Amy adds her experience in personalized medicine, outcomes research, clinical trials and patient centered care to the CareDx team. With many similarities and cross-over between the oncology and transplant patient populations, there is ample opportunity to translate learnings from one area to the other.
“I look forward to working with the CareDx management team at an exciting time in the company’s history,” said Amy Abernethy. “CareDx is poised as a leader in transplantation and can bring real value to patients through their access to data and focus on long term outcomes.”
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap and AlloSure for post-transplant surveillance and Olerup SSP, Olerup QTYPE, Olerup SBT, and TruSight for pre-transplant HLA testing.
For more information : http://www.caredx.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
